HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy.
COVID-19
HLA class I
SARS-Cov2
coronavirus
viral infection susceptibility
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Jul 2020
23 Jul 2020
Historique:
received:
04
06
2020
revised:
06
07
2020
accepted:
10
07
2020
entrez:
29
7
2020
pubmed:
29
7
2020
medline:
13
8
2020
Statut:
epublish
Résumé
The spread of COVID-19 is showing huge, unexplained, differences between northern and southern Italy. We hypothesized that the regional prevalence of specific class I human leukocyte antigen (HLA) alleles, which shape the anti-viral immune response, might partly underlie these differences. Through an ecological approach, we analyzed whether a set of HLA alleles (A, B, C), known to be involved in the immune response against infections, correlates with COVID-19 incidence. COVID-19 data were provided by the National Civil Protection Department, whereas HLA allele prevalence was retrieved through the Italian Bone-Marrow Donors Registry. Among all the alleles, HLA-A*25, B*08, B*44, B*15:01, B*51, C*01, and C*03 showed a positive log-linear correlation with COVID-19 incidence rate fixed on 9 April 2020 in proximity of the national outbreak peak (Pearson's coefficients between 0.50 and 0.70,
Identifiants
pubmed: 32717807
pii: ijms21155205
doi: 10.3390/ijms21155205
pmc: PMC7432860
pii:
doi:
Substances chimiques
HLA-B44 Antigen
0
HLA-C Antigens
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
J Virol. 2020 Jun 16;94(13):
pubmed: 32303592
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Br Med Bull. 2005 Feb 08;71:93-113
pubmed: 15701924
Tissue Antigens. 2002 Apr;59(4):338-40
pubmed: 12135438
Front Immunol. 2019 May 28;10:1179
pubmed: 31231370
Tissue Antigens. 1989 Jan;33(1):21-9
pubmed: 2711369
Science. 1992 Mar 6;255(5049):1261-3
pubmed: 1546328
J Exp Med. 1989 Sep 1;170(3):797-810
pubmed: 2788708
Int J Infect Dis. 2020 May;94:55-58
pubmed: 32251791
Front Immunol. 2019 Jun 19;10:1415
pubmed: 31316503
HLA. 2020 Aug;96(2):194-196
pubmed: 32424945
Clin Dev Immunol. 2010;2010:539519
pubmed: 20976125
J Infect Dis. 2015 Sep 15;212(6):939-47
pubmed: 25740956
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Front Immunol. 2016 Jul 25;7:281
pubmed: 27504110
J Immunol Res. 2018 Feb 25;2018:3174868
pubmed: 29682588
J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):356-361
pubmed: 29528943
J Pharm Anal. 2020 Apr;10(2):102-108
pubmed: 32282863
Endocr Metab Immune Disord Drug Targets. 2007 Jun;7(2):99-109
pubmed: 17584150
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
F1000Res. 2020 Feb 25;9:145
pubmed: 32269766
JAMA. 2020 Mar 17;:
pubmed: 32181795
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):121-31
pubmed: 17106278
J Immunol. 1991 Mar 1;146(5):1692-9
pubmed: 1671580
Gastroenterology. 2000 Feb;118(2):274-8
pubmed: 10648455
PLoS Pathog. 2012;8(7):e1002805
pubmed: 22807681
Nature. 1991 May 23;351(6324):290-6
pubmed: 1709722
Dermatoendocrinol. 2016 Jan 08;8(1):e1137400
pubmed: 27195055
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Immunol. 2006 Jun;119(3):346-50
pubmed: 16542878
Front Immunol. 2020 May 28;11:1208
pubmed: 32574270
Immunotherapy. 2019 Dec;11(18):1523-1526
pubmed: 31865873
HIV Med. 2017 Sep;18(8):587-594
pubmed: 28218480
Inflamm Bowel Dis. 2016 Apr;22(4):796-806
pubmed: 26891255
Sci Rep. 2014 Aug 07;4:5981
pubmed: 25099678
HLA. 2019 Sep;94(3):285-295
pubmed: 31207125
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508